Sandbox 215: Difference between revisions
From Proteopedia
Jump to navigationJump to search
/* Mechanism allowing neutral-lipid and phospholipid transfer <ref name="rasmol" /> <ref name="rasmol1">James A Hamilton & Richard J Deckelbaum. Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nature S |
|||
| Line 74: | Line 74: | ||
The pharmaceutical industry tries to develop inhibitors of CETP in order to decrease the risk of cardivascular diseases. The goal of these inhibitors is to increase the concentration of HDL and decrease the concentration of LDL by blocking cholesteryl esters and triglyceride tranfer. Several inhibitors were found: the first is Torcetrapib followed of Anacetrapib, Dalcetrapib and Evacetrapib. | The pharmaceutical industry tries to develop inhibitors of CETP in order to decrease the risk of cardivascular diseases. The goal of these inhibitors is to increase the concentration of HDL and decrease the concentration of LDL by blocking cholesteryl esters and triglyceride tranfer. Several inhibitors were found: the first is Torcetrapib followed of Anacetrapib, Dalcetrapib and Evacetrapib. | ||
Torcetrapib was developed by Pfizer in order to treat hypercholesterolemia (high cholesterol levels) and prevent [http://en.wikipedia.org/wiki/Atherosclerosis atherosclerosis]. Torcetrapib managed to reduce CETP activity and succeeds in increasing the level of HDL. However, in stage-III clinical trials, Torcetrapib causes significant changes in vital signs: like increases the blood pressure, the concentration of sodium, bicarbonate and aldosterone. The explanations for this unexpected result remain unclear | Torcetrapib was developed by Pfizer in order to treat hypercholesterolemia (high cholesterol levels) and prevent [http://en.wikipedia.org/wiki/Atherosclerosis atherosclerosis]. Torcetrapib managed to reduce CETP activity and succeeds in increasing the level of HDL. However, in stage-III clinical trials, Torcetrapib causes significant changes in vital signs: like increases the blood pressure, the concentration of sodium, bicarbonate and aldosterone. The explanations for this unexpected result remain unclear but perhaps increased binding of torcetrapib-CETP complexes to HDL may interfer with the anti-cardiovascular diseases (anti-CVD) activity of HDL causing the death of many persons. That's why, in 2006, this inhibitor was halted. | ||
Unlike to Torcetrapib, the other which still are in clinical trial do not have any side effects. | Unlike to Torcetrapib, the other which still are in clinical trial do not have any side effects. | ||
